

Correlates of protective immunity for Ebola vaccines: in approval by the animal rule

Nature Reviews Microbiology

7, 393-400

DOI: [10.1038/nrmicro2129](https://doi.org/10.1038/nrmicro2129)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Protecting against Future Shock – Inhalational Anthrax. <i>New England Journal of Medicine</i> , 2009, 361, 191-193.	13.9	5
3	Discovery of common marburgvirus protective epitopes in a BALB/c mouse model. <i>Virology Journal</i> , 2009, 6, 132.	1.4	9
4	Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. <i>Virology</i> , 2010, 399, 290-298.	1.1	45
5	Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. <i>Virology</i> , 2010, 401, 228-235.	1.1	77
6	A Monoclonal Immunoglobulin G Antibody Directed against an Immunodominant Linear Epitope on the Ricin A Chain Confers Systemic and Mucosal Immunity to Ricin. <i>Infection and Immunity</i> , 2010, 78, 552-561.	1.0	77
7	Demonstration of Cross-Protective Vaccine Immunity against an Emerging Pathogenic Ebolavirus Species. <i>PLoS Pathogens</i> , 2010, 6, e1000904.	2.1	106
8	Recent advances in Ebolavirus vaccine development. <i>Hum Vaccin</i> , 2010, 6, 439-449.	2.4	44
9	Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices. <i>Vaccine</i> , 2010, 28, 2137-2148.	1.7	17
10	A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. <i>Vaccine</i> , 2010, 29, 304-313.	1.7	186
11	Filovirus vaccines: what challenges are left?. <i>Expert Review of Vaccines</i> , 2010, 9, 5-8.	2.0	4
12	Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines against Angola Marburg Virus in Nonhuman Primates. <i>Journal of Virology</i> , 2010, 84, 10386-10394.	1.5	64
13	Tackling Ebola: new insights into prophylactic and therapeutic intervention strategies. <i>Genome Medicine</i> , 2011, 3, 5.	3.6	20
14	Progress in filovirus vaccine development: evaluating the potential for clinical use. <i>Expert Review of Vaccines</i> , 2011, 10, 63-77.	2.0	90
15	CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. <i>Nature Medicine</i> , 2011, 17, 1128-1131.	15.2	200
16	Highly effective generic adjuvant systems for orphan or poverty-related vaccines. <i>Vaccine</i> , 2011, 29, 873-877.	1.7	35
17	Whither monkeypox vaccination. <i>Vaccine</i> , 2011, 29, D60-D64.	1.7	32
18	Ebola haemorrhagic fever. <i>Lancet</i> , The, 2011, 377, 849-862.	6.3	1,101
19	Differential requirements for clathrin endocytic pathway components in cellular entry by Ebola and Marburg glycoprotein pseudovirions. <i>Virology</i> , 2011, 419, 1-9.	1.1	40

#	ARTICLE	IF	CITATIONS
20	Mucosal Vaccines for Biodefense. <i>Current Topics in Microbiology and Immunology</i> , 2011, 354, 181-195.	0.7	11
21	Vesicular Stomatitis Virus-Based Ebola Vaccines With Improved Cross-Protective Efficacy. <i>Journal of Infectious Diseases</i> , 2011, 204, S1066-S1074.	1.9	102
22	Recombinant Adenovirus Serotype 26 (Ad26) and Ad35 Vaccine Vectors Bypass Immunity to Ad5 and Protect Nonhuman Primates against Ebolavirus Challenge. <i>Journal of Virology</i> , 2011, 85, 4222-4233.	1.5	176
23	Filovirus vaccines. <i>Hum Vaccin</i> , 2011, 7, 701-711.	2.4	29
24	Inactivated or Live-Attenuated Bivalent Vaccines That Confer Protection against Rabies and Ebola Viruses. <i>Journal of Virology</i> , 2011, 85, 10605-10616.	1.5	75
25	Correlates of Immunity to Filovirus Infection. <i>Viruses</i> , 2011, 3, 982-1000.	1.5	35
26	Protective Role of Cytotoxic T Lymphocytes in Filovirus Hemorrhagic Fever. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-13.	3.0	18
27	Antigenic Subversion: A Novel Mechanism of Host Immune Evasion by Ebola Virus. <i>PLoS Pathogens</i> , 2012, 8, e1003065.	2.1	146
28	Anthrax Vaccine-Induced Antibodies Provide Cross-Species Prediction of Survival to Aerosol Challenge. <i>Science Translational Medicine</i> , 2012, 4, 151ra126.	5.8	52
29	Immune Parameters Correlate with Protection Against Ebola Virus Infection in Rodents and Nonhuman Primates. <i>Science Translational Medicine</i> , 2012, 4, 158ra146.	5.8	135
30	Ebolavirus vaccines for humans and apes. <i>Current Opinion in Virology</i> , 2012, 2, 324-329.	2.6	37
31	Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein. <i>Vaccine</i> , 2012, 30, 6136-6141.	1.7	27
32	A Single Sublingual Dose of an Adenovirus-Based Vaccine Protects against Lethal Ebola Challenge in Mice and Guinea Pigs. <i>Molecular Pharmaceutics</i> , 2012, 9, 156-167.	2.3	49
33	Ebolavirus: a brief review of novel therapeutic targets. <i>Future Microbiology</i> , 2012, 7, 1-4.	1.0	28
34	Investigation of Ebola VP40 Assembly and Oligomerization in Live Cells Using Number and Brightness Analysis. <i>Biophysical Journal</i> , 2012, 102, 2517-2525.	0.2	72
35	Mucosal Vaccines. <i>Current Topics in Microbiology and Immunology</i> , 2012, , .	0.7	2
36	Ad35 and Ad26 Vaccine Vectors Induce Potent and Cross-Reactive Antibody and T-Cell Responses to Multiple Filovirus Species. <i>PLoS ONE</i> , 2012, 7, e44115.	1.1	52
37	Designing and Testing Broadly-Protective Filoviral Vaccines Optimized for Cytotoxic T-Lymphocyte Epitope Coverage. <i>PLoS ONE</i> , 2012, 7, e44769.	1.1	20

#	ARTICLE	IF	CITATIONS
38	Current ebola vaccines. Expert Opinion on Biological Therapy, 2012, 12, 859-872.	1.4	76
39	A new player in the puzzle of filovirus entry. Nature Reviews Microbiology, 2012, 10, 317-322.	13.6	70
40	Vaccines for viral hemorrhagic feversâ€™ progress and shortcomings. Current Opinion in Virology, 2013, 3, 343-351.	2.6	48
41	Ebola vaccine. , 2013, , 1060-1067.		0
42	Characterization of a putative filovirus vaccine: Virus-like particles. Virologica Sinica, 2013, 28, 65-70.	1.2	6
44	Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb. Scientific Reports, 2013, 3, 3365.	1.6	93
45	Airway Delivery of an Adenovirus-Based Ebola Virus Vaccine Bypasses Existing Immunity to Homologous Adenovirus in Nonhuman Primates. Journal of Virology, 2013, 87, 3668-3677.	1.5	66
46	Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine. PLoS Pathogens, 2013, 9, e1003389.	2.1	106
47	Profile and Persistence of the Virus-Specific Neutralizing Humoral Immune Response in Human Survivors of Sudan Ebolavirus (Gulu). Journal of Infectious Diseases, 2013, 208, 299-309.	1.9	47
49	Complex Correlates of Protection After Vaccination. Clinical Infectious Diseases, 2013, 56, 1458-1465.	2.9	225
50	Antibodies are necessary for rVSV/ZEBOV-GPâ€™ mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1893-1898.	3.3	236
51	Durability of a Vesicular Stomatitis Virus-Based Marburg Virus Vaccine in Nonhuman Primates. PLoS ONE, 2014, 9, e94355.	1.1	67
52	A New Approach for Monitoring Ebolavirus in Wild Great Apes. PLoS Neglected Tropical Diseases, 2014, 8, e3143.	1.3	41
53	Ebola Vaccination: If Not Now, When?. Annals of Internal Medicine, 2014, 161, 749.	2.0	30
54	Ebola Hemorrhagic Fever and the Current State of Vaccine Development. Osong Public Health and Research Perspectives, 2014, 5, 378-382.	0.7	7
55	Vaccination with recombinant adenoviruses expressing Ebola virus glycoprotein elicits protection in the interferon alpha/beta receptor knock-out mouse. Virology, 2014, 452-453, 324-333.	1.1	10
56	Vaccinating captive chimpanzees to save wild chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8873-8876.	3.3	31
57	Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nature Medicine, 2014, 20, 1126-1129.	15.2	311

#	ARTICLE	IF	CITATIONS
58	Ebola: an analysis of immunity at the molecular level. , 2015, , .		1
59	Progress of vaccine and drug development for Ebola preparedness. <i>Clinical and Experimental Vaccine Research</i> , 2015, 4, 11.	1.1	29
60	Mechanisms of Immunity in Post-Exposure Vaccination against Ebola Virus Infection. <i>PLoS ONE</i> , 2015, 10, e0118434.	1.1	18
61	Alternative Animal Toxicity Testing of Chemical Warfare Agents. , 2015, , 657-673.		1
62	Molecular mechanisms of Ebola virus pathogenesis: focus on cell death. <i>Cell Death and Differentiation</i> , 2015, 22, 1250-1259.	5.0	127
63	Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses. <i>Journal of Infectious Diseases</i> , 2015, 212, S414-S424.	1.9	49
65	Cross-Protection Conferred by Filovirus Virus-Like Particles Containing Trimeric Hybrid Glycoprotein. <i>Viral Immunology</i> , 2015, 28, 62-70.	0.6	20
66	Ebola in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 868-871.	1.5	3
67	Ebola and Marburg vaccines for Africa: one step closer. <i>Lancet, The</i> , 2015, 385, 1491-1493.	6.3	4
68	Immune Memory to Sudan Virus: Comparison between Two Separate Disease Outbreaks. <i>Viruses</i> , 2015, 7, 37-51.	1.5	20
69	Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study. <i>Journal of Infectious Diseases</i> , 2015, 212, S389-S397.	1.9	18
70	Humanitarian Access to Unapproved Interventions in Public Health Emergencies of International Concern. <i>PLoS Medicine</i> , 2015, 12, e1001793.	3.9	14
71	Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques. <i>Journal of Virology</i> , 2015, 89, 6773-6781.	1.5	58
72	Characterization of Immune Responses Induced by Ebola Virus Glycoprotein (GP) and Truncated GP Isoform DNA Vaccines and Protection Against Lethal Ebola Virus Challenge in Mice. <i>Journal of Infectious Diseases</i> , 2015, 212, S398-S403.	1.9	17
73	A vaccine against Ebola: Problems and opportunities. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1258-1260.	1.4	6
74	Drug and Vaccine Access in the Ebola Epidemic: Advising Caution in Compassionate Use. <i>Annals of Internal Medicine</i> , 2015, 162, 141-142.	2.0	11
75	Immunology of protection from Ebola virus infection. <i>Science Translational Medicine</i> , 2015, 7, 286ps11.	5.8	18
76	Clinical development of Ebola vaccines. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 125-138.	2.7	65

#	ARTICLE	IF	CITATIONS
77	Adenovirus-vectored Ebola vaccines. <i>Expert Review of Vaccines</i> , 2015, 14, 1347-1357.	2.0	17
78	Development of vaccines for prevention of Ebola virus infection. <i>Microbes and Infection</i> , 2015, 17, 98-108.	1.0	23
79	How the Current West African Ebola Virus Disease Epidemic Is Altering Views on the Need for Vaccines and Is Galvanizing a Global Effort to Field-Test Leading Candidate Vaccines. <i>Journal of Infectious Diseases</i> , 2015, 211, 504-507.	1.9	10
80	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. <i>Microbiology Spectrum</i> , 2016, 4, .	1.2	3
81	How are Vaccines Assessed in Clinical Trials?. , 2016, , 97-119.		0
82	Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge. <i>PLoS ONE</i> , 2016, 11, e0162446.	1.1	26
83	Vaccines for Emerging Viral Diseases. , 2016, , 543-560.		1
84	Circulating follicular T helper cells and cytokine profile in humans following vaccination with the rVSV-ZEBOV Ebola vaccine. <i>Scientific Reports</i> , 2016, 6, 27944.	1.6	72
85	Ebola virus vaccines – reality or fiction?. <i>Expert Review of Vaccines</i> , 2016, 15, 1421-1430.	2.0	29
86	Ebola virus disease candidate vaccines under evaluation in clinical trials. <i>Expert Review of Vaccines</i> , 2016, 15, 1101-1112.	2.0	50
87	Ebola vaccines – Where are we?. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2700-2703.	1.4	3
88	An Inactivated Rabies Virus–Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models. <i>Journal of Infectious Diseases</i> , 2016, 214, S342-S354.	1.9	32
89	Cytomegalovirus-based vaccine expressing Ebola virus glycoprotein protects nonhuman primates from Ebola virus infection. <i>Scientific Reports</i> , 2016, 6, 21674.	1.6	54
90	Vaccine development: From concept to early clinical testing. <i>Vaccine</i> , 2016, 34, 6655-6664.	1.7	82
91	Ebola virus vaccines: Where do we stand?. <i>Clinical Immunology</i> , 2016, 173, 44-49.	1.4	32
92	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	13.9	295
93	Duration of immune responses after Ebola virus vaccination. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 2-3.	4.6	4
94	Ebola Viral Glycoprotein Bound to Its Endosomal Receptor Niemann-Pick C1. <i>Cell</i> , 2016, 164, 258-268.	13.5	226

#	ARTICLE	IF	CITATIONS
95	Quantitative serology assays for determination of antibody responses to Ebola virus glycoprotein and matrix protein in nonhuman primates and humans. <i>Antiviral Research</i> , 2016, 126, 55-61.	1.9	11
96	Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 31-42.	4.6	187
97	Adjuvant-enhanced CD4 T Cell Responses are Critical to Durable Vaccine Immunity. <i>EBioMedicine</i> , 2016, 3, 67-78.	2.7	49
98	Ebola virus disease: emergence, outbreak and future directions. <i>British Medical Bulletin</i> , 2016, 117, 95-106.	2.7	21
99	Antibody therapeutics for Ebola virus disease. <i>Current Opinion in Virology</i> , 2016, 17, 45-49.	2.6	45
100	Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus. <i>Virus Research</i> , 2016, 213, 224-229.	1.1	23
101	Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease. <i>Journal of Infectious Diseases</i> , 2016, 213, 703-711.	1.9	65
102	Chimpanzee Adenovirus Vector Ebola Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 928-938.	13.9	243
103	One Step Closer to an Ebola Virus Vaccine. <i>New England Journal of Medicine</i> , 2017, 376, 984-985.	13.9	12
104	IgG Fc variant cross-reactivity between human and rhesus macaque Fc γ 3Rs. <i>MAbs</i> , 2017, 9, 455-465.	2.6	21
105	Complex immune correlates of protection in HIV-1 vaccine efficacy trials. <i>Immunological Reviews</i> , 2017, 275, 245-261.	2.8	95
106	Selective inhibition of Ebola entry with selective estrogen receptor modulators by disrupting the endolysosomal calcium. <i>Scientific Reports</i> , 2017, 7, 41226.	1.6	41
107	Global research trends of World Health Organization's top eight emerging pathogens. <i>Globalization and Health</i> , 2017, 13, 9.	2.4	144
108	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	1.8	33
109	Dose-dependent T-cell Dynamics and Cytokine Cascade Following rVSV-ZEBOV Immunization. <i>EBioMedicine</i> , 2017, 19, 107-118.	2.7	64
110	Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice. <i>Journal of Virology</i> , 2017, 91, .	1.5	23
111	Advances in Ebola virus vaccination. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 787-788.	4.6	2
112	T-cell-dependent mechanisms promote Ebola VLP-induced antibody responses, but are dispensable for vaccine-mediated protection. <i>Emerging Microbes and Infections</i> , 2017, 6, 1-9.	3.0	13

#	ARTICLE	IF	CITATIONS
113	Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG. <i>Scientific Reports</i> , 2017, 7, 41537.	1.6	14
114	Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles. <i>Journal of Virology</i> , 2017, 91, .	1.5	22
115	Ebola virus “epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans “ an update on its 40 year's journey. <i>Veterinary Quarterly</i> , 2017, 37, 98-135.	3.0	33
116	Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 621-628.	6.3	168
117	Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial. <i>The Lancet Global Health</i> , 2017, 5, e324-e334.	2.9	85
118	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	1.4	67
119	Graphene-VP40 interactions and potential disruption of the Ebola virus matrix filaments. <i>Biochemical and Biophysical Research Communications</i> , 2017, 493, 176-181.	1.0	18
120	Windows of opportunity for Ebola virus infection treatment and vaccination. <i>Scientific Reports</i> , 2017, 7, 8975.	1.6	34
121	A heterologous prime-boost Ebola virus vaccine regimen induces durable neutralizing antibody response and prevents Ebola virus-like particle entry in mice. <i>Antiviral Research</i> , 2017, 145, 54-59.	1.9	10
122	Toward an Effective Ebola Virus Vaccine. <i>Annual Review of Medicine</i> , 2017, 68, 371-386.	5.0	29
123	Development of a Lethal Intranasal Exposure Model of Ebola Virus in the Cynomolgus Macaque. <i>Viruses</i> , 2017, 9, 319.	1.5	21
124	Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins. <i>Journal of Virology</i> , 2018, 92, .	1.5	36
125	A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge. <i>Scientific Reports</i> , 2018, 8, 864.	1.6	43
126	From bench to almost bedside: the long road to a licensed Ebola virus vaccine. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 159-173.	1.4	35
127	Vaccines against Ebola virus. <i>Vaccine</i> , 2018, 36, 5454-5459.	1.7	43
128	Virulence of Marburg Virus Angola Compared to Mt. Elgon (Musoke) in Macaques: A Pooled Survival Analysis. <i>Viruses</i> , 2018, 10, 658.	1.5	13
129	Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?. <i>Expert Review of Vaccines</i> , 2018, 17, 1105-1110.	2.0	14
130	Establishing China's National Standard for the Recombinant Adenovirus Type 5 Vector-Based Ebola Vaccine (Ad5-EBOV) Virus Titer. <i>Human Gene Therapy Clinical Development</i> , 2018, 29, 226-232.	3.2	11

#	ARTICLE	IF	CITATIONS
131	Ebola: Lessons on Vaccine Development. Annual Review of Microbiology, 2018, 72, 423-446.	2.9	51
132	Safeguarding against Ebola: Vaccines and therapeutics to be stockpiled for future outbreaks. PLoS Neglected Tropical Diseases, 2018, 12, e0006275.	1.3	10
133	Ebola Immunity: Gaining a Winning Position in Lightning Chess. Journal of Immunology, 2018, 201, 833-842.	0.4	19
134	Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. Scientific Reports, 2018, 8, 11193.	1.6	26
135	Correlates of vaccine-induced protective immunity against Ebola virus disease. Seminars in Immunology, 2018, 39, 65-72.	2.7	44
136	Role of Antibodies in Protection Against Ebola Virus in Nonhuman Primates Immunized With Three Vaccine Platforms. Journal of Infectious Diseases, 2018, 218, S553-S564.	1.9	22
137	Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. International Journal of Infectious Diseases, 2018, 74, 83-96.	1.5	21
138	Systematic Analysis of Monoclonal Antibodies against Ebola Virus GP Defines Features that Contribute to Protection. Cell, 2018, 174, 938-952.e13.	13.5	173
139	Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebola Virus Glycoprotein. Viral Immunology, 2018, 31, 500-512.	0.6	3
140	An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques. Emerging Microbes and Infections, 2018, 7, 1-12.	3.0	16
141	Correlates of Protection. , 2018, , 35-40.e4.		22
142	Ebola Vaccines. , 2018, , 276-287.e5.		0
143	Recombinant subunit vaccines protect guinea pigs from lethal Ebola virus challenge. Vaccine, 2019, 37, 6942-6950.	1.7	15
144	Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. Journal of Virology, 2019, 93, .	1.5	26
145	Deciphering Fc-mediated Antiviral Antibody Functions in Animal Models. Frontiers in Immunology, 2019, 10, 1602.	2.2	4
146	T-Cell Response to Viral Hemorrhagic Fevers. Vaccines, 2019, 7, 11.	2.1	30
147	Emerging and Enabling Technologies in Biodefense. , 2019, , 253-281.		3
148	Development, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS ONE, 2019, 14, e0215457.	1.1	35

#	ARTICLE	IF	CITATIONS
150	Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebola virus. <i>Cell Reports</i> , 2019, 29, 2537-2545.e3.	2.9	7
151	Current Ebola Virus Vaccine Progress. <i>BioDrugs</i> , 2019, 33, 9-14.	2.2	32
152	Updates on immunologic correlates of vaccine-induced protection. <i>Vaccine</i> , 2020, 38, 2250-2257.	1.7	119
153	Towards quantification of protective antibody responses by passive transfer of the 1st WHO International Standard for Ebola virus antibody in a guinea pig model. <i>Vaccine</i> , 2020, 38, 345-349.	1.7	4
154	To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity. <i>Microorganisms</i> , 2020, 8, 1473.	1.6	12
155	Multifaceted Immune Responses to African Swine Fever Virus: Implications for Vaccine Development. <i>Veterinary Microbiology</i> , 2020, 249, 108832.	0.8	31
156	Ebola Virus Disease Survivors Show More Efficient Antibody Immunity than Vaccinees Despite Similar Levels of Circulating Immunoglobulins. <i>Viruses</i> , 2020, 12, 915.	1.5	13
157	Arranging good clinical practices training and trial monitoring for a vaccine efficacy study during a public health emergency of international concern. <i>Vaccine</i> , 2020, 38, 4050-4056.	1.7	1
158	Alternative animal toxicity testing of chemical warfare agents. , 2020, , 853-871.		0
159	A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques. <i>Journal of Virology</i> , 2020, 94, .	1.5	17
160	Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2855-2860.	1.4	7
161	A model for establishment, maintenance and reactivation of the immune response after vaccination against Ebola virus. <i>Journal of Theoretical Biology</i> , 2020, 495, 110254.	0.8	13
162	Ebola virus antibody decayâ€“stimulation in a high proportion of survivors. <i>Nature</i> , 2021, 590, 468-472.	13.7	30
163	Development of a Well-Characterized Rhesus Macaque Model of Ebola Virus Disease for Support of Product Development. <i>Microorganisms</i> , 2021, 9, 489.	1.6	10
164	Ebola-GP DNA Prime rAd5-GP Boost: Influence of Prime Frequency and Prime/Boost Time Interval on the Immune Response in Non-human Primates. <i>Frontiers in Immunology</i> , 2021, 12, 627688.	2.2	3
165	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. <i>Frontiers in Immunology</i> , 2021, 12, 682120.	2.2	9
166	Ebola vaccineâ€“induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	22
167	Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. <i>PLoS ONE</i> , 2021, 16, e0252874.	1.1	11

#	ARTICLE	IF	CITATIONS
168	Cross-Neutralisation of Novel Bombali Virus by Ebola Virus Antibodies and Convalescent Plasma Using an Optimised Pseudotype-Based Neutralisation Assay. <i>Tropical Medicine and Infectious Disease</i> , 2021, 6, 155.	0.9	2
169	Immunological mechanisms associated with clinical features of Ebola virus disease and its control and prevention. , 2021, , 159-183.		0
170	Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate. <i>Npj Vaccines</i> , 2020, 5, 112.	2.9	45
171	Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection. <i>PLoS ONE</i> , 2013, 8, e56265.	1.1	123
172	Homologous and Heterologous Protection of Nonhuman Primates by Ebola and Sudan Virus-Like Particles. <i>PLoS ONE</i> , 2015, 10, e0118881.	1.1	50
173	A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. <i>PLoS ONE</i> , 2018, 13, e0192312.	1.1	64
174	Method feasibility for cross-species testing, qualification, and validation of the Filovirus Animal Nonclinical Group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for non-human primate serum samples. <i>PLoS ONE</i> , 2020, 15, e0241016.	1.1	7
176	Ebolavirus Vaccines. , 2013, , 119-134.		0
177	Preparing for Serious Communicable Diseases in the United States: What the Ebola Virus Epidemic Has Taught Us. , 0, , 39-52.		0
180	Antiviral Strategies for Ebola Virus and Other Filoviruses: Antibodies. <i>RSC Drug Discovery Series</i> , 2021, , 91-120.	0.2	0
181	Predictors of Survival after Vaccination in a Pneumonic Plague Model. <i>Vaccines</i> , 2022, 10, 145.	2.1	6
183	Neutralizing Antibody Titer Test of Ebola Recombinant Protein Vaccine and Gene Vector Vaccine pVR-GP-FC. <i>Biomedical and Environmental Sciences</i> , 2018, 31, 721-728.	0.2	1
185	Doubly robust evaluation of high-dimensional surrogate markers. <i>Biostatistics</i> , 2023, 24, 985-999.	0.9	0
186	Assays for the Evaluation of the Immune Response to Marburg and Ebola Sudan Vaccination” Filovirus Animal Nonclinical Group Anti-Marburg Virus Glycoprotein Immunoglobulin G Enzyme-Linked Immunosorbent Assay and a Pseudovirion Neutralization Assay. <i>Vaccines</i> , 2022, 10, 1211.	2.1	5
187	Bridging Animal and Human Data in Pursuit of Vaccine Licensure. <i>Vaccines</i> , 2022, 10, 1384.	2.1	3
188	A platform technology for generating subunit vaccines against diverse viral pathogens. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
189	Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
190	Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola. <i>Npj Vaccines</i> , 2022, 7, .	2.9	9

#	ARTICLE	IF	CITATIONS
191	A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
192	Recent updates on correlates of vaccine-induced protection. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
193	Approaches to demonstrating the effectiveness of filovirus vaccines: Lessons from Ebola and COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
194	Accelerating antiviral drug discovery: lessons from COVID-19. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 585-603.	21.5	25
196	Ebola Vaccines. , 2023, , 311-329.e6.		0
197	Correlates of Protection. , 2023, , 45-51.e5.		1
200	Ebola virus disease in children: epidemiology, pathogenesis, management, and prevention. <i>Pediatric Research</i> , 2024, 95, 488-495.	1.1	1